Cargando…
Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira)
Due to the progressive nature of type 2 diabetes (T2D), the majority of patients require increasing levels of therapy to achieve and maintain good glycemic control. At present, once patients become uncontrolled on oral antidiabetic therapies, the two primary treatment options are glucagon-like pepti...
Autores principales: | Morales, Javier, Merker, Ludwig |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449377/ https://www.ncbi.nlm.nih.gov/pubmed/25962992 http://dx.doi.org/10.1007/s12325-015-0208-2 |
Ejemplares similares
-
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
por: Gough, Stephen CL, et al.
Publicado: (2016) -
Physicians’ real-world experience with IDegLira: results of a European survey
por: Drummond, Russell, et al.
Publicado: (2018) -
Correction: Physicians’ real-world experience with IDegLira: results of a European survey
Publicado: (2018) -
Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden
por: Eliasson, Björn, et al.
Publicado: (2020) -
Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM
por: Kawaguchi, Yuji, et al.
Publicado: (2022)